Stocks · News reference

What's Going On With BioVie Stock on Tuesday?

Sep 15, 2026, 4:21 PMVandana Singh

BioVie reported Phase 2 ADDRESS-LC trial results evaluating bezisterim for Long COVID, showing significant subgroup improvements.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Sep 15, 2026, 4:21 PM
Checked: Sep 15, 2026, 4:21 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 15, 2026, 2:18 PMBenzinga Newsdesk
BioVie shares are trading lower. The company announced topline results from Phase 2 ADDRESS‑LC trial evaluating Bezisterim for the treatment of neurological symptoms associated with long COVID.
BIVI
BenzingaSep 15, 2026, 11:55 AMBenzinga Newsdesk
Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times
BIVI
BenzingaSep 15, 2026, 11:32 AMBenzinga Newsdesk
BioVie Announces Phase 2 ADDRESS-LC Trial Results Of Bezisterim In Long COVID
Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaiseBezisterim showed a
BIVI